Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?

× No keyword cloud information.

13 in total

1. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.

Authors: Steven P Schulman; Lewis C Becker; David A Kass; Hunter C Champion; Michael L Terrin; Sandra Forman; Kavita V Ernst; Mark D Kelemen; Susan N Townsend; Anne Capriotti; Joshua M Hare; Gary Gerstenblith
Journal: JAMA Date: 2006-01-04 Impact factor: 56.272

2. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors: Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal: N Engl J Med Date: 2004-11-08 Impact factor: 91.245

Review 3. Managing cardiovascular risk in minority patients.

Authors: Keith C Ferdinand
Journal: J Natl Med Assoc Date: 2005-04 Impact factor: 1.798

4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:
Journal: JAMA Date: 2002-12-18 Impact factor: 56.272

5. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

Authors: P Carson; S Ziesche; G Johnson; J N Cohn
Journal: J Card Fail Date: 1999-09 Impact factor: 5.712

6. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction.

Authors: Anna Helgadottir; Andrei Manolescu; Agnar Helgason; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Solveig Gretarsdottir; Kristinn P Magnusson; Gudmundur Gudmundsson; Andrew Hicks; Thorlakur Jonsson; Struan F A Grant; Jesus Sainz; Stephen J O'Brien; Sigurlaug Sveinbjornsdottir; Einar M Valdimarsson; Stefan E Matthiasson; Allan I Levey; Jerome L Abramson; Murdach P Reilly; Viola Vaccarino; Megan L Wolfe; Vilmundur Gudnason; Arshed A Quyyumi; Eric J Topol; Daniel J Rader; Gudmundur Thorgeirsson; Jeffrey R Gulcher; Hakon Hakonarson; Augustine Kong; Kari Stefansson
Journal: Nat Genet Date: 2005-11-10 Impact factor: 38.330

7. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

Authors: D V Exner; D L Dries; M J Domanski; J N Cohn
Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245

8. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Authors: C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer
Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245

9. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks.

Authors: Allen Burke; Wendy Creighton; Erik Mont; Ling Li; Susan Hogan; Robert Kutys; David Fowler; Renu Virmani
Journal: Circulation Date: 2005-08-01 Impact factor: 29.690

Review 10. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.

Authors: Keith C Ferdinand; Claudia C Serrano; Daphne P Ferdinand
Journal: Curr Hypertens Rep Date: 2002-08 Impact factor: 5.369